A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
Official Title ICMJE A Phase 2, Open-Label, Multi-Center, Single Arm Study to Evaluate the Efficacy and Safety of TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection
Sponsor: First Hospital of China Medical University
This PHASE2 trial investigates Adjuvant Therapy and Hepatocellular Carcinoma and is currently ongoing. First Hospital of China Medical University leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Jan 2025 — Present [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Feb 2022 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- First Hospital of China Medical University
- Hainan People's Hospital
- Shandong Cancer Hospital and Institute
- The Affiliated Hospital Of Southwest Medical University
- Tianjin Third Central Hospital
- Zhejiang University
For direct contact, visit the study record on ClinicalTrials.gov .